41 results about "Oral feeding" patented technology

Generally, the present invention relates to medical devices and more particularly to an computer controlled bottle system for example, for a preterm infant oral feeding. An embodiment of the invention is directed to a method for delivering nutritional fluids orally to a preterm infant comprising the steps of measuring the infant's inspired breath to breath amplitude, measuring the infant's intraoral sucking pressure, establishing threshold values for infant's inspired breath to breath amplitude and infant's intraoral sucking pressure, and delivering nutritional fluids to the infant only when the infant's inspired breath to breath amplitude and infant's intraoral sucking pressure both simultaneously satisfy their respective threshold values.

Devices and methods were discovered that successfully provided patient autonomous control of both hyolaryngeal elevation, anterior hyoid motion and opening of the upper esophageal sphincter for swallowing by intramuscular stimulation of two muscles. The technology allows patient self stimulation of swallowing and can return oral feeding to dysphagia patients. Indwelling electrode stimulation of only two muscles generated as much as 80 % of normal synergistic movement leading to swallowing. The devices and methods also are useful for control of other upper respiratory muscle groups involved in speech and voice. Calibration techniques may be used in combination for greater freedom in setting and using electrodes over extended implantation time periods. These methods and devices can control complex movements of body solids such as bone and cartilage and tissues by electro stimulation of a minimum set of muscles simultaneously.

A feeding device and a method for facilitating the transition from non-oral tube feeding to oral feeding is disclosed. The device comprises a fluid reservoir having a fluid outlet, a nipple having a fluid outlet, a shield attached to the nipple base, a conduit for conveying fluid from the reservoir to the nipple fluid outlet and a manually adjustable valve that is operable to prevent and control the flow of fluid through the conduit. The method comprises the steps of providing a device of the type just described, acclimating an infant to the device by closing the valve and inserting the nipple into the infant's mouth. The valve is then opened to permit the very slow flow of fluid through the nipple outlet. Additional feeding regimens are provided in which restriction of the flow of fluid is gradually relaxed over a series of feedings until the infant is able to withdraw about sixty cubic centimeters of fluid during a twenty minute feeding without distress.

A feeding device especially for facilitating the transition from non-oral tube feeding to oral feeding is disclosed. The device comprises a fluid reservoir-having a fluid outlet, a nipple having a fluid outlet, a conduit for conveying fluid from the reservoir to the nipple fluid outlet and a manually adjustable valve that includes a manually settable selector to control the flow of fluid through the conduit and to vary it from zero flow to substantial flow. The device may include a shield associated with the nipple.

Anaphylactic diseases comprising urticaria, papilla, subacute dermatitis, eczema, and the like, are skin diseases which seriously puzzle the human beings. In the invention, antihistamine, zinc salt and weak acid are prepared into a topical compound preparation, which not only reduces the untoward effect of drugs, avoids the first pass effect of the liver when feeding the drugs by mouth, avoids the blood concentration peak valley phenomenon caused by oral feeding, but also can improve the curative effect and is convenient for clinic application. Simultaneously pharmacological tests show that the topical compound preparation obtains excellent drug synergism to the anaphylactic skin diseases and has excellent effects on curing the anaphylactic diseases.

The present invention relates to a system device and method for monitoring infant oral motor kinetics (OMK), which can be used to assess the functional significance of the different sucking components, i.e., the plasticity of infant sucking skills in relation to their oral feeding performance, at a particular time, during the developmental period and/or during preventive or therapeutic intervention programs. It is a unique system and apparatus that provides a means to study the nonnutritive and/or nutritive sucking skills, i.e., the Suction and/or Expression components of sucking, of infants in the natural setting, i.e., during a normal feeding session. OMK sensors, tracked in real-time by the monitoring system, include miniature pressure transducers, or pressure sensitive pads, attached to the nipple for measuring intraoral pressure pulses during Suction, and for measuring compression/stripping pressure pulses during Expression; and a miniature flow sensor for measuring fluid flow rate, which can be integrated over time to determine the volume of milk removed (bolus) per suck. Other signals, such as respiration, swallowing, thermal, optical, and acoustic signals can be recorded and compared along with the instrumented-nipple signals, in an OMK monitoring system.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.

Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

The invention discloses a natural animal feed additive which comprises the following components in mass percentage: 10-25% of allicin, 1-5% of beta-glucanase, 20-40% of diatomaceous earth, 5-15% of potassium sorbate, 25-50% of beer yeast cell wall and 0.5-1% of vitamin C. Mixing materials which are 0.01-5% of the dry weight of the natural animal feed additive is added in the natural animal feed additive; and by carrying out oral feeding every day, the natural animal feed additive can be used for preventing and treating the infection from causative agents such as fungus, bacterium and virus causative agents to the animals, so that the immunity and the adversity resistance of various farmed animals are strengthened, the antibiotic used multi-component complex formula products are decreased, the inborn and acquired immunities of the animals can be strengthened, the response of the organism to various vaccines is remarkably improved so as to strengthen the comprehensive immunological competence of the organism for diseases, the death rate can be remarkably reduced at the paedomorphosis stage of the animals and the weight increment capability and other production capabilities of the animals can be improved at the adult growth state.

The invention relates to a compound immunopotentiator, particularly to a compound immunopotentiator for rachycentron canadum fries, and belongs to the field of feed additives for rachycentron canadum fries. The compound immunopotentiator for the rachycentron canadum fries is prepared from the following components (by wt%): Beta-glucan 20-25%, vitamin C-2-polyphosphonate 5-20%, vitamin E 8-15%, FeSO4*7H2O 5-20%, sodium selenite 0.2-0.5%, astragalus membranaceus 10-35%, radix bupleuri 5-20%, and glucose 5-30%. The compound immunopotentiator can be directly added into the feed of the rachycentron canadum fries for oral feeding or sprinkled over water where the rachycentron canadum fries live; and can remarkably improve the immunity and the disease resistance of the rachycentron canadum fries. The compound immunopotentiator has the advantages of no toxic and adverse residues, no drug resistance, environmental friendliness, no adverse effect on feed palatability, stable source of raw materials, and simple production process.

The present disclosure relates to a therapeutic system and methods of using the therapeutic system. In particular, the present disclosure relates to a system for improving an oral feeding ability of a patient including an assessment device to contact a patient and collect data related to an oral feeding ability of the patient, a computing device containing a processor to execute an assessment and therapy application, and the assessment and therapy application to receive the data related to the oral feeding ability, predict one or more areas of neurological muscle activity that need further development, and develop a neurological therapy treatment for improving the one or more areas of neurological muscle activity that need further development.

The invention discloses an artificial domestication method of glyptosternum maculatum wild parent fish, and belongs to the technical field of aquaculture. The artificial domestication method comprisesthe steps of selecting wild glyptosternum maculatum parent fish; preparing a domestication pond; carrying out domestication of the parent fish; performing a paste bait feeding stage; feeding the parent fish with the paste bait by adopting an artificial oral feeding method on the day of fishing and transportation, and placing the parent fish in the domestication pond after transportation; performing a paste bait and live loach feeding stage; adopting live loaches to gradually replace paste baits for feeding, wherein the replacement method comprises the steps of carrying out feeding by the paste baits and the live loaches for 4-5 days according to the frequency ratio of 2 to 1 every day, and conducting feeding for three times every day; afterwards, carrying out feeding by the paste baits and the live loaches for 4-5 days according to the frequency ratio of 1 to 2 every day, and conducting feeding for three times every day; next, carrying out feeding with only the live loaches for 4-5 days, and conducting feeding for three times every day; executing a live loach feeding stage; after the feeding stage of the paste bait and the live loaches, continuously feeding by the live loaches; and conducting feeding twice a day. The method is used for artificial domestication of the glyptosternum maculatum wild parent fish.

The invention relates to trans-cellulase gene recombinant lactobacilli and a product and application of the trans-cellulase gene recombinant lactobacilli. Protein coded by the trans-cellulase gene recombinant lactobacilli has an amino acid sequence shown in a sequence table SEQ ID NO.1. The trans-cellulase gene recombinant lactobacilli built by the invention can be used as an oral feed additive applied to the pig industry or poultry farming so as to compensate the defects that intestinal tracts of pigs, and birds cannot secrete cellulose without adding expensive cellulase preparation, not only facilitates metabolism of crude fiber in feed material, but also can promote growth of pigs and increase the economic benefits of cultivation. In addition, the host bacterium lactobacillus is lactobacillus casei, and has a probiotic function to an animal body. The invention provides an artificial cellulase probiotic genetic engineering lactobacillus, which has important application value in production of monogastric animals such as pigs, birds and the like.

The invention provides a compound walnut and linseed oil fat emulsion intravenous injection and a preparation method thereof. The compound walnut and linseed oil fat emulsion intravenous injection comprises the raw materials of walnut oil, linseed oil, lecithin, glycerol, sterile pure water, antioxidants, stabilizing agents, pH regulating agents and the like. The preparation method comprises the following steps of: under the protection of nitrogen, heating, dissolving and mixing the walnut oil, the linseed oil and the lecithin into an oil phase; mixing the glycerol, the antioxidants, the stabilizing agents and the sterile pure water into a water phase, slowly adding the oil phase in the violently stirred water phase and then shearing in high speed to form a primary emulsion; and regulating the pH of the primary emulsion to 6.5-8.5 by using a few pH regulating agents, emulsifying by using a high-pressure viscolizer, filtering by using a microporous membrane, and then filling, sealing and sterilizing to obtain the compound walnut and linseed oil fat emulsion intravenous injection, wherein the total oil content of the intravenous injection is 1%-50%. The compound walnut and linseed oil fat emulsion intravenous injection and the preparation method thereof are used in the fields of medical treatment and health, and the compound walnut and linseed oil fat emulsion intravenous injection can be administrated through abenteric intravenous injection or intestinal tube feeding or oral feeding and can be used as a nutritional and therapeutic medicament.

The invention relates to a self-assembling protein for forming a pharmaceutical compound, belonging to the technical field of biology. The self-assembling protein has an amino acid residue sequence shown in SEQ ID NO 1 as well as a general formula as follows: QQCTTGQLQCCESTSTANDPATSELLGLIGVVISDVDA LVGLTCSPISVIGVGSGSACTANPVCCDSSPIGGLVSIGCVPVNV SEQ ID NO 1. A supporting agent based on the self-assembling protein and a pharmaceutical composition prepared from the supporting agent can be used as oral feeding medication carriers of GLP-1 for treating type 2 diabetes mellitus.